Treatment for Specific Types of Skin Lymphoma

The treatment of skin lymphoma is based mainly on the type of lymphoma a person has, as well as its location and its stage – how far it has spread. But other factors, such as your overall health, can also affect your treatment options. Talk to your doctor if you have any questions about the treatment plan he or she recommends.

The treatments mentioned in this section fall into 2 main groups:

Along with treatments aimed at the lymphoma itself, supportive care treatments for symptoms such as itching or skin infections are also often an important part of care for people with skin lymphomas. This type of treatment is often given by a dermatologist, a doctor who treats diseases of the skin.

T-cell lymphomas

Mycosis fungoides (MF)

Many forms of treatment can be used for MF.

Skin-directed treatments: For early stages of MF, treatments are aimed at the skin. Options may include:

  • Phototherapy with ultraviolet (UV) light (either UVB light or UVA combined with drugs called psoralens, known as PUVA)
  • Topical chemotherapy with BCNU or nitrogen mustard
  • Topical corticosteroid ointments or injections
  • Topical retinoids (vitamin A-like drugs), such as bexarotene
  • Topical imiquimod (a form of immune therapy)
  • Local radiation treatments, if there is only one or a few lesions
  • Total skin electron beam therapy (TSEBT) if MF covers most of the skin

Sometimes more than one type of skin-directed treatment is used.

Systemic (whole-body) treatments: Mycosis fungoides might stay just in the skin for many years. But eventually it might spread, which might require systemic treatment. Several types of treatment can be used, such as:

  • Retinoids (taken by mouth)
  • Targeted drugs like vorinostat (Zolinza) or romidepsin (Istodax)
  • Photopheresis
  • Interferons
  • Brentuximab vedotin (Adcetris)
  • Mogamulizumab (Poteligeo)
  • Pembrolizumab (Keytruda)
  • Low-dose methotrexate (a chemo drug)

Chemotherapy (usually with a single drug) or other medicines might also be options, but they are often reserved for lymphomas that are no longer responding to the treatments above. If single chemo drugs are not effective, combinations of drugs (similar to those used for other types of non-Hodgkin lymphoma) might be recommended.

More than one type of treatment might be used at the same time. This could include combinations of skin-directed and systemic treatments (such as TSEBT plus photopheresis) or combined systemic treatments (such as an oral retinoid plus interferon).

Many people can be helped by these treatments, sometimes for many years, but they rarely cure the lymphoma. If other treatments are no longer working, a stem cell transplant may be an option. Newer treatments are also being studied, so it might be worth considering entering a clinical trial.

Sezary syndrome

The systemic treatments used for advanced MF (see above) are also used to treat Sezary syndrome. This disease usually has spread beyond the skin at the time it is diagnosed, so treatments directed only at the skin are less useful than in MF (although some might still be part of treatment).

Photopheresis may be helpful in treating the disease, as may retinoids, such as bexarotene. The targeted drugs vorinostat (Zolinza) and romidepsin (Istodax) might also be used, as might interferon, brentuximab vedotin (Adcetris), or mogamulizumab (Poteligeo). Chemotherapy or other drugs such as alemtuzumab or pembrolizumab (Keytruda) might also be useful, but these are usually reserved for lymphomas that are no longer responding to other treatments. A stem cell transplant might be another option if other treatments are no longer working.

As with advanced MF, these treatments are often helpful for a time, but they rarely result in a cure. Newer treatments are now being studied, so it might be worth considering entering a clinical trial of one of these.

Primary cutaneous anaplastic large cell lymphoma (C-ALCL)

This lymphoma usually stays confined to the skin. It can come back after treatment, but it seldom spreads inside the body and is rarely fatal. If it’s not causing symptoms, it can often be watched closely without needing to be treated right away. The skin lesions may even go away on their own, without any treatment.

If treatment is needed, options depend on how extensive the lymphoma is:

  • For single skin lesions (or small groups of lesions), surgery and/or radiation therapy are the most common options. 
  • If there are skin lesions in several places, the targeted drug brentuximab vedotin (Adcetris) or chemotherapy (often methotrexate, taken as a pill) is often the first treatment. Other chemotherapy, targeted therapy, or retinoid drugs might also be options, as well as radiation therapy (and possibly other skin-directed treatments).

If the lymphoma comes back in the same place after treatment, the same treatment often can be used again. If one treatment is no longer helpful, another can be tried.

If the lymphoma spreads to the lymph nodes or (rarely) internal organs, brentuximab vedotin (Adcetris), chemotherapy, or a combination of the two might be options. Sometimes radiation therapy might be given as well.

Lymphomatoid papulosis

This disease often comes and goes on its own and usually has such a good outlook that treatment isn't needed right away, especially if the lesions aren't causing any symptoms. If treatment is needed, options depend on how extensive it is:

  • If there are only a few skin lesions, topical corticosteroids or phototherapy is the most common treatment.
  • If the lesions are more extensive, skin-directed treatments (such as phototherapy or topical chemotherapy or corticosteroids) or systemic treatments (such as oral retinoids or low-dose methotrexate) are options.

More intensive systemic therapies are rarely needed.

Subcutaneous panniculitis-like T-cell lymphoma

People with this rare type of lymphoma can live a long time and generally have an excellent outlook. This disease can often be controlled for long periods with just corticosteroids. Chemotherapy, radiation, or newer treatments might also be options, if needed.

Primary cutaneous peripheral T-cell lymphoma, rare subtypes

Primary cutaneous gamma/delta T-cell lymphoma tends to grow and spread very quickly. It is treated with systemic chemotherapy using a combination of drugs, but even with treatment it can often be hard to control.

Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma usually grows quickly and is treated with systemic chemotherapy using a combination of drugs. Even with treatment, it can often be hard to control.

Primary cutaneous acral CD8+ T-cell lymphoma tends to grow slowly, and can usually be treated effectively with surgery or radiation therapy. It can sometimes come back, but it can often be treated again in the same way.

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder sometimes goes away on its own. If treatment is needed, it is usually surgery or radiation therapy, or by injecting a corticosteroid into the tumor. People with this lymphoma generally have a very good outlook, especially if they have only one tumor.

Some of these lymphomas can be hard to treat effectively, so clinical trials studying newer forms of treatment might be good options.

B-cell lymphomas

Primary cutaneous marginal zone B-cell lymphoma or
Primary cutaneous follicle center lymphoma

These types of skin lymphoma tend to have a good outlook. They can sometimes be watched without treatment until problems develop, but usually treatment is recommended.

For lymphomas that are in one spot or only a few spots close together, initial treatment is usually radiation therapy or surgery. Other options might include topical medicines such as corticosteroids, chemotherapy, bexarotene (Targretin), or imiquimod (Zyclara); or injected corticosteroids. If the lymphoma does not go away completely, one of the other treatments can be tried.

For lymphomas that have spread over larger parts of the skin, treatment options include rituximab (Rituxan), topical medicines (such as corticosteroids, chemotherapy, bexarotene, or imiquimod), injected corticosteroids, or radiation therapy. Systemic chemotherapy (sometimes with rituximab), like that used for other slow-growing B-cell lymphomas, can also be used if there are many lesions.

If the lymphoma has spread to lymph nodes or internal organs, it is treated like follicular lymphoma or marginal zone lymphoma found in other parts of the body, such as with a combination of chemotherapy and rituximab. To learn more, see Treating B-Cell Non-Hodgkin Lymphoma.

Primary cutaneous diffuse large B-cell lymphoma, leg type

These lymphomas might look like they involve only a small area of the skin at first, but the disease is often more widespread than it appears. The treatment of choice is usually rituximab (Rituxan) along with systemic chemotherapy. Often the regimen called R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is given, but other combinations can also be used. If the lymphoma is in only one or a few areas, radiation therapy directed at the tumors is often used as well. For people who can’t get chemo for some reason, radiation therapy alone may be given.

If the lymphoma has spread to the lymph nodes or other organs, treatment is the same as that used for diffuse large B-cell lymphomas (DLBCLs) found in other parts of the body. To learn more, see Treating B-Cell Non-Hodgkin Lymphoma.

If the lymphoma keeps growing or comes back after treatment

Some skin lymphomas respond well to treatment, but others might not. If this happens, other types of treatment can often be tried. But as more treatments are tried, they may be less likely to work or more likely to cause side effects.

When a cancer comes back after treatment it is called recurrent or relapsed. In general, if a skin lymphoma comes back it tends to be in the skin. If this is the case, skin-directed therapies that haven’t been used yet may be effective.

Some skin lymphomas eventually spread inside the body as well. Often, the lymph nodes are the first site of relapse. After that, the lymphoma might spread to organs such as the liver or spleen, or bone marrow. Different types of systemic treatments may be helpful in this situation. Chemotherapy might be used, especially if a person hasn’t had chemo before. Depending on the type of lymphoma and treatments a person has had before, other options might include drugs such as vorinostat (Zolinza), romidepsin (Istodax), brentuximab vedotin (Adcetris), mogamulizumab (Poteligeo), or pembrolizumab (Keytruda). A stem cell transplant may be another option at some point.

Advanced skin lymphomas can be very hard to cure. Different systemic treatments may be effective for some time, but in general, the more treatments a person has had, the less likely it is that the next treatment will be helpful.

A good option for some people might be to consider entering a clinical trial that's testing a newer type of treatment. Many newer treatments are now being studied. For more info, see What’s New in Skin Lymphoma Research? 

Written by
References

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.

 

Hoppe RT, Kim YH, Horwitz S. Treatment of advanced-stage (IIB to IV) mycosis fungoides. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/treatment-of-advanced-stage-iib-to-iv-mycosis-fungoides on May 30, 2024.

Hoppe RT, Kim YH, Horwitz S. Treatment of early stage (IA to IIA) mycosis fungoides. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/treatment-of-early-stage-ia-to-iia-mycosis-fungoides on May 30, 2024.

Jacobsen E. Primary cutaneous anaplastic large cell lymphoma. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/primary-cutaneous-anaplastic-large-cell-lymphoma on May 31, 2024.

Jacobsen E, Freedman AS, Willemze R. Primary cutaneous large B cell lymphoma, leg type. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/primary-cutaneous-large-b-cell-lymphoma-leg-type on May 31, 2024.

Kadin ME. Lymphomatoid papulosis. UpToDate. 2024. Accessed at www.uptodate.com/contents/lymphomatoid-papulosis on May 31, 2024.

Kim EJ, Rook AH. Treatment of Sézary syndrome. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/treatment-of-sezary-syndrome on May 30, 2024.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Primary Cutaneous Lymphomas. Version 2.2024. Accessed at https://www.nccn.org on May 29, 2024.

Querfeld C, Rosen ST, Duvic M. Chapter 104: Cutaneous T-cell lymphoma and cutaneous B-cell lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier: 2020.

Willemze R. Primary cutaneous T cell lymphomas, rare subtypes. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/primary-cutaneous-t-cell-lymphomas-rare-subtypes on May 31, 2024.

 

Last Revised: June 3, 2024

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.